
Datopotamab Deruxtecan Shows Promise in EGFR-Mutated NSCLC
A pooled analysis of the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials demonstrated that datopotamab deruxtecan (Dato-DXd) achieved significant clinical responses in patients with previously treated advanced or metastatic…












